| Nucala (mepolizumab) / GSK |
ACTRN12618000850279: How to "choosebetweenamab" for severe asthma, comparing treatment with mepolizumab and omalizumab for patients with severe allergic and eosinophilic asthma. |
|
|
| Recruiting | 4 | 200 | | | Peter Wark, Glaxo Smith Kline | severe asthma | | | | |
2008-002353-20: an open-label study to evaluate safety and efficacy of 750 mg intravenous mepolizumab in subjects with steroid refractory eosinophilic cystitis |
|
|
| Ongoing | 4 | 1 | Europe | mepolizumab, BS-240563 | UZ Gasthuisberg | eosinophilic cystitis | | | | |
2018-002591-40: Evaluation of bronchial remodeling during mepolizumab treatment in severe eosinophilic asthma Evaluation du remodelage bronchique lors d’un traitement par mépolizumab dans l’asthme sévère éosinophile |
|
|
| Not yet recruiting | 4 | 40 | Europe | Powder for solution for injection, Nucala | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, LABORATOIRE GLAXOSMITHKLINE | severe oesinophilic asthma asthme sévère éosinophile, severe oesinophilic asthma asthme sévère éosinophile, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2016-002014-52: DUAL HOMING MECHANISMS OF EOSINOPHILS TO THE SPUTUM; ONLY ONE OF WHICH IS SENSITIVE FOR MEPOLIZUMAB; The FOOTSTEP study HET EFFECT VAN EEN NIEUW GENEESMIDDEL, NUCALA®, OP HET AFWEERSYSTEEM VAN MENSEN MET ASTMA: DE VOETSTAP STUDIE |
|
|
| Not yet recruiting | 4 | 20 | Europe | Nucala, SB-240563, Nucala | University Medical Center Utrecht, GlaxoSmithKline | severe eosinophilic asthma, Treatment of patients with severe asthma that do not sufficiently respond to current treatment, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2020-000421-76: Aggravated airway inflammation: research on biological treatment (Mepolizumab) AirGOs-biologics |
|
|
| Ongoing | 4 | 120 | Europe | Nucala, R03DX09, Injection, Nucala 100mg/dose, injection, R03DX09 | Helsinki University Hospital, GSK investigator sponsored study | A triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma and NSAID exacerbated respiratory disease (NERD), Tutkimme yhteensä 120 vaikeaa tulehduskipulääkeyliherkkyyttä, eli NERD:ä, sekä nenäpolypoosia ja astmaa sairastavaa potilasta, Diseases [C] - Ear, nose and throat diseases [C09] | | | | |
NCT05001529: Flow Cytometry Analysis of Eosinophils in Severe Asthma Patients. |
|
|
| Recruiting | 4 | 80 | Europe | anti IL5 receptor antibodies | Scarlata, Simone, M.D., IRCCS San Raffaele | Severe Asthma | 03/22 | 03/23 | | |
NCT04585997: Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab". |
|
|
| Recruiting | 4 | 200 | RoW | Mepolizumab, Nucala, Omalizumab, Xolair | University of Newcastle, Australia, GlaxoSmithKline | Asthma, Eosinophilic Asthma | 06/22 | 12/22 | | |
2019-004676-18: Comparison of the mode of action of two anti-asthma drugs, mepolizumab and benralizumab, during treatment of asthma patients with moderate to severe asthma. Vergelijking van de werkingsmechanismen van twee anti-astma medicijnen, mepolizumab en benralizumab, tijdens de behandeling van patiënten met matig tot ernstig astma. |
|
|
| Not yet recruiting | 4 | 72 | Europe | Nucala, Fasenra, SB-240563, IW-8405, Solution for injection in pre-filled pen, Nucala, Fasenra | University Medical Center Utrecht, GlaxoSmithKline | severe eosinophilic asthma ernstig eosinofiel astma, Treatment of patients with severe asthma that do not sufficiently respond to current treatment Behandeling van patiënten met ernstig asthma die niet goed op huidige therapie responderen, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2022-002923-37: Optimisation of treatment in patients with chronic rhinosinusitis with nasal polyps. A clinical trial investigating the difference between biological treatment with Mepolizumab and Functional endoscopic sinus surgery (FESS) versus biological treatment with mepolizumab without sinus surgery. |
|
|
| Not yet recruiting | 4 | 52 | Europe | Mepolizumab, EMEA/H/C/003860-IB/0051, Injection, Mepolizumab | Department of Otorhinolaryngology Head & Neck and Audiology, Rigshospitalet, Copenhagen, Denmark, ISS grant from GlaxoSmithKline | Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma, Chronic rhinosinusitis with nasal polyps and asthma, Diseases [C] - Ear, nose and throat diseases [C09] | | | | |
2020-003358-63: OPTIMAL - Individualized dosetitration of biological treatment in severe asthma |
|
|
| Not yet recruiting | 4 | 150 | Europe | Nucala, Fasenra, Cinqaero | Bispebjerg Hospital, Bispebjerg Hospital | Severe asthma, Asthma that requires two or more types of asthma medications, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
PRISM, NCT04276233: Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma |
|
|
| Completed | 4 | 100 | RoW | Mepolizumab, Salbutamol | GlaxoSmithKline, Tech Observer | Asthma | 10/23 | 10/23 | | |
| Recruiting | 4 | 100 | Europe | Randomisation to omalizumab, Active-controlled, Randomisation to mepolizumab | Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital, Ghent, University of Liege, CHU de Charleroi, Erasme University Hospital, Centre Hospitalier Universitaire Dinant Godinne - UCL Namur, Universitair Ziekenhuis Brussel, Brugmann University Hospital, Grand Hôpital de Charleroi, AZ Delta, Centre Hospitalier Universitaire Saint Pierre, KU Leuven | Severe Asthma | 12/23 | 12/24 | | |
MUCOSA, NCT04765722: Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases |
|
|
| Active, not recruiting | 4 | 30 | Canada | Mepolizumab, Nucala, Normal Saline, 0.09% normal saline | McMaster University, University of Manchester | Chronic Cough, Eosinophilic Bronchitis, Asthma | 11/24 | 12/24 | | |
NCT05642806: Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment |
|
|
| Recruiting | 4 | 90 | Canada | Mepolizumab, Placebo | St. Paul's Sinus Centre | Chronic Rhinosinusitis With Nasal Polyps, Asthma, Chronic Rhinosinusitis Without Nasal Polyps | 12/24 | 06/25 | | |
NCT05598814: Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks |
|
|
| Recruiting | 4 | 52 | Europe | Mepolizumab Injection, Functional Endoscopic Sinus Surgery (FESS). | Vibeke Backer | Chronic Rhinosinusitis With Nasal Polyps, Asthma | 01/25 | 08/25 | | |
MELYSA, NCT05923047: Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study. |
|
|
| Not yet recruiting | 4 | 75 | Europe | Mepolizumab, Polypeptomy | Instituto de Investigación Marqués de Valdecilla | Rhinosinusitis Chronic, Polyp, Nasal | 09/24 | 12/24 | | |
| Not yet recruiting | 4 | 40 | Canada | Mepolizumab | St. Paul's Sinus Centre | Chronic Rhinosinusitis With Nasal Polyps | 01/25 | 01/25 | | |
TORNADO, NCT05942222: A Randomized, Real-world Head-to-head Study of Dupilumab Versus Mepolizumab in Danish CRSwNP Patients |
|
|
| Recruiting | 4 | 220 | Europe | dupilumab, Dupixent, mepolizumab, Nucala | Rigshospitalet, Denmark | Chronic Rhinosinusitis With Nasal Polyps, Asthma; Eosinophilic, Eosinophilia | 02/26 | 03/26 | | |
SECURE, NCT05626777: Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices |
|
|
| Recruiting | 4 | 130 | Europe | Pre-filled syringe, mepolizumab 100 mg/month, Auto-injector pen, mepolizumab 100 mg/month | Hospices Civils de Lyon, GlaxoSmithKline | Asthma | 03/26 | 07/26 | | |
REIMAGINE, NCT06041386: - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study |
|
|
| Not yet recruiting | 4 | 336 | NA | Mepolizumab, NUCALA, Spirometry | GlaxoSmithKline | Asthma | 07/26 | 07/26 | | |
| Recruiting | 4 | 36 | Canada | Mepolizumab 100 MG Injection, Nucala | Centre hospitalier de l'Université de Montréal (CHUM) | Chronic Rhinosinusitis With Nasal Polyps | 12/26 | 12/26 | | |
| Ongoing | 3 | 55 | Europe | Mepolizumab, SB240563, | GlaxoSmithKline Research and Development Limited, GlaxoSmithKline Research and Development Limited | Subjects with severe, refractory asthma and a history of eosinophilic inflammation. | | | | |
2012-004385-17: Study of mepolizumab versus placebo in addition to standard of care for the treatment of Eosinophilic Granulomatosis with Polyangiitis. |
|
|
| Ongoing | 3 | 20 | Europe | Mepolizumab, SB-240563, | GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A., GlaxoSmithKline | Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy. | | | | |
2013-004297-98: English Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations. |
|
|
| Ongoing | 3 | 65 | Europe | mepolizumab, SB-240563, | GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline | Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations | | | | |
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Mepolizumab 40mg or 100mg | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Asthma | 12/19 | 12/19 | | |
| Completed | 3 | 100 | Europe, Canada, Japan, US | Mepolizumab, Prednisolone | GlaxoSmithKline | Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis | 02/23 | 02/23 | | |
MERIT, NCT04607005: Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS) |
|
|
| Completed | 3 | 169 | Japan, RoW | Mepolizumab, Placebo, Standard of care | GlaxoSmithKline, BioClinica, Inc., Signant Health | Nasal Polyps | 04/23 | 04/23 | | |
| Active, not recruiting | 3 | 140 | Europe, Canada, Japan, US, RoW | Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab | AstraZeneca | Eosinophilic Granulomatous Vasculitis | 08/23 | 03/26 | | |
|
|
|
| Active, not recruiting | 3 | 806 | Europe, Canada, Japan, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
| Recruiting | 3 | 25 | Europe, US, RoW | Mepolizumab | GlaxoSmithKline | Hypereosinophilic Syndrome | 09/24 | 09/24 | | |
SUMMER, NCT05138250: A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD |
|
|
| Recruiting | 3 | 32 | Europe | Mepolizumab 100 MG | Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield | COPD | 12/24 | 05/25 | | |
E-merge, NCT05030155: Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis |
|
|
| Recruiting | 3 | 100 | Europe | Mepolizumab, cyclophosphamide/azathioprine, Placebo | Assistance Publique - Hôpitaux de Paris, French Vasculitis Study Group, URC-CIC Paris Descartes Necker Cochin | Eosinophilic Granulomatosis With Polyangiitis | 11/25 | 11/25 | | |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) |
|
|
| Recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab | GlaxoSmithKline | Eosinophilic Granulomatosis With Polyangiitis | 10/25 | 11/25 | | |
| Completed | 2/3 | 238 | Europe | Mepolizumab, Placebo, Saline solution | University of Leicester, GlaxoSmithKline | COPD, Eosinophilia | 06/24 | 06/24 | | |
2005-001932-61: Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. |
|
|
| Ongoing | 2 | 60 | Europe | Mepolizumab, SB-240563, | University Hospitals of Leicester | Refractory Eosinophilic Asthma. | | | | |
NCT05320939: Immunological Basis for Mepolizumab Activity in COPD |
|
|
| Not yet recruiting | 2 | 30 | NA | Mepolizumab 100 MG | Temple University, GlaxoSmithKline | COPD | 04/24 | 05/25 | | |
| Recruiting | 2 | 18 | RoW | Mepolizumab low dose group, Mepolizumab middle dose group, Mepolizumab high dose group, Saline | Xijing Hospital | Coronary Artery Disease | 09/25 | 03/26 | | |
NCT05576454: Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects |
|
|
| Completed | 1 | 207 | RoW | Mepolizumab Injection (BAT2606 Injection), BAT2606 Injection, Mepolizumab Injection (EU-licensed Nucala), EU-licensed Nucala, Mepolizumab Injection (US-licensed Nucala), US-licensed Nucala | Bio-Thera Solutions | Severe Asthma | 05/23 | 06/23 | | |
NCT03494881: Mepolizumab for the Treatment of Chronic Spontaneous Urticaria |
|
|
| Active, not recruiting | 1 | 24 | US | Nucala, Mepolizumab | Mayo Clinic, GlaxoSmithKline | Chronic Spontaneous Urticaria | 11/23 | 09/24 | | |
| Recruiting | 1 | 8 | US | Mepolizumab, Nucala | Johns Hopkins University, GlaxoSmithKline | Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis) | 01/25 | 06/25 | | |
| Withdrawn | 1 | 6 | NA | Mepolizumab, Nucala | Mayo Clinic, GlaxoSmithKline | Eosinophilic Fasciitis | 12/25 | 12/25 | | |
| Not yet recruiting | N/A | 80 | | | University of Newcastle, Glaxo Smith Kline | Severe Asthma | | | | |
ACTRN12623000692639: Australian Mepolizumab Registry for Chronic Rhinosinusitis with Nasal Polyps (AMR-CRSwNP) |
|
|
| Not yet recruiting | N/A | 140 | | | The University of Newcastle, GlaxoSmithKline | chronic rhinosinusitis with nasal polyps | | | | |
NCT00244686 / 2007-000838-39: This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic |
|
|
| No Longer Available | N/A | | NA | Mepolizumab | GlaxoSmithKline | Hypereosinophilic Syndrome | | | | |
| Completed | N/A | 109 | Canada | IL5/IL5R Antagonists, mepolizumab, benralizumab | Hopital du Sacre-Coeur de Montreal, GlaxoSmithKline | Severe Asthma | 06/23 | 11/23 | | |
NCT05189613: Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis |
|
|
| Recruiting | N/A | 100 | Europe | Mepolizumab | Policlinico Universitario, Catania | Bronchial Asthma, Bronchiectasis | 06/22 | 12/22 | | |
NCT05063981: Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma With or Without CRSwNP. |
|
|
| Recruiting | N/A | 20 | Europe | Mepolizumab, Nucala | Istituti Clinici Scientifici Maugeri SpA | Asthma, Nasal Polyps, Sinusitis Chronic | 11/24 | 12/24 | | |
NCT04665141: Similarities and Differences of Biological Therapies for Severe Asthma. |
|
|
| Recruiting | N/A | 600 | Europe | Mepolizumab, Nucala®, Omalizumab, Xolair®, Reslizumab, Cinqair®, Benralizumab, Fasenra®, Dupilumab, Dupixent® | Clinica Universidad de Navarra, Universidad de Navarra, Hospital Clinic of Barcelona, Hospital Regional de Malaga | Asthma | 11/22 | 11/22 | | |
| Not yet recruiting | N/A | 60 | NA | Mepolizumab, nucala | Laval University, GlaxoSmithKline | Asthma | 01/23 | 01/23 | | |
NCT05002621: Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma |
|
|
| Completed | N/A | 20 | US | | Mayo Clinic | Eosinophilic Asthma | 02/23 | 02/23 | | |
MARS, NCT04551989: Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan |
|
|
| Completed | N/A | 118 | Japan | | GlaxoSmithKline | Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis | 04/23 | 04/23 | | |
NCT06348173: Response and Remission to Treatment With Anti-IL5/IL5R Antagonists |
|
|
| Completed | N/A | 109 | Canada | Mepolizumab, benralizumab | Université de Montréal, GlaxoSmithKline | Asthma | 11/23 | 11/23 | | |
| Active, not recruiting | N/A | 45 | Europe | Mepolizumab 100 MG [Nucala], biological/vaccine | Aristotle University Of Thessaloniki, NHS Pulmonary Clinic G. Papanikolaou Hospital, Thessaloniki, Greece, Pulmonary Clinic of Army Hospital Thessaloniki Greece, Pulmonary Clinic, Democritus University of Thrace, Pulmonary Clinic, University of Ioannina, 1st Pulmonary Clinic, Kapodistrian University of Athens, 2nd Pulmonary Clinic, Kapodistrian University of Athens, NHS 7th Pulmonary Clinic, Sotiria Hospital, Athens | Asthma; Eosinophilic, Severe Asthma, Late-Onset Asthma | 03/23 | 03/25 | | |
| Completed | N/A | 7938 | Europe | Mepolizumab | University Hospital, Montpellier | Asthma | 07/23 | 07/23 | | |
| Recruiting | N/A | 70 | Europe | Mepolizumab 100 MG | Università degli Studi di Ferrara, GlaxoSmithKline | Severe Asthma | 09/23 | 12/23 | | |
| Recruiting | N/A | 500 | RoW | Biological Treatment for severe asthma patients, Omalizumab, Mepolizumab, Benralizumab, Dupilzumab, Tezepelumab | Taichung Veterans General Hospital, E-DA Hospital, National Cheng-Kung University Hospital, National Yang Ming Chiao Tung University Hospital, Chang Gung Memorial Hospital | Pulmonary Disease, Asthma | 02/43 | 02/43 | | |
| Active, not recruiting | N/A | 110 | Europe | Mepolizumab, Placebo | Helsinki University Central Hospital | Asthma, Aspirin-Induced, Chronic Rhinosinusitis with Nasal Polyps | 12/24 | 12/25 | | |
| Recruiting | N/A | 30 | Europe | Mepolizumab 100 MG | Hospital Clinico Universitario de Santiago, GlaxoSmithKline | Asthma, Eosinophilic Asthma | 12/23 | 03/25 | | |
| Recruiting | N/A | 180 | Europe | Mepolizumab, Omalizumab, Dupilumab | University Hospital, Ghent | Chronic Rhinosinusitis With Nasal Polyps | 12/30 | 12/30 | | |
CASAM, NCT05139381: Study for Children & Adolescent With Severe Asthma With an Eosinophilic Phenotype Treated With Mepolizumab |
|
|
| Active, not recruiting | N/A | 148 | Europe | Mepolizumab | King's College Hospital NHS Trust | Asthma in Children | 03/26 | 03/26 | | |
NCT03028480: Long Term Special Drug Use Investigation of Mepolizumab |
|
|
| Completed | N/A | 1061 | NA | NUCALA Injection | GlaxoSmithKline | Asthma | 11/23 | 11/23 | | |
MEPOREAL, NCT06258772: Mepolizumab in the Treatment of Patients With Severe Uncontrolled CRSwNP: a Multicentric Real Life Observational Study |
|
|
| Not yet recruiting | N/A | 199 | Europe | Mepolizumab Auto-Injector, Mepolizumab 100 mg | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Chronic Rhinosinusitis With Nasal Polyps | 02/25 | 02/26 | | |
NCT06298448: eGPA and Local Inflammation Within the Ear, Nose and Throat Area |
|
|
| Recruiting | N/A | 150 | Europe | laboratory experiments before and after mepolizumab treatment | University Medical Center Groningen, GlaxoSmithKline | EGPA - Eosinophilic Granulomatosis With Polyangiitis | 12/27 | 12/28 | | |
NCT03557060: NUCALA® Special Drug Use Investigation (EGPA, Long-term) |
|
|
| Active, not recruiting | N/A | 300 | Japan | Nucala | GlaxoSmithKline | Churg-Strauss Syndrome | 05/24 | 05/24 | | |
| Not yet recruiting | N/A | 900 | Europe | Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval). | University Hospital, Lille | Rhinosinusitis Chronic, Nasal Polyps | 09/34 | 01/35 | | |
| Not yet recruiting | N/A | 48 | NA | Biological Drug, Mepolizumab, Omalizumab, Benralizumab, Dupilimab, Reslizumab | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Asthma | 09/24 | 09/24 | | |
| Recruiting | N/A | 120 | Europe | no study intervention. Patients receive standard clinical care, no intervention. observational study | University Hospital Southampton NHS Foundation Trust, Portsmouth Hospitals NHS Trust, University of Derby | Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression, Psychological Stress, Psychological Adjustment, Psychological Disorder, Psychosocial Problem, Psychosocial Stressor, Psychological, Emotions, Emotional Disorder, Emotional Dysfunction, Emotional Distress, Adjustment, Adjustment, Emotional, Coping Behavior | 12/24 | 12/24 | | |
FUNLUM, NCT04512521: Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma |
|
|
| Recruiting | N/A | 40 | Europe | Mepolizumab | Hannover Medical School, GlaxoSmithKline | Asthma; Eosinophilic | 02/25 | 08/25 | | |
| Recruiting | N/A | 50 | Europe | blood sample | University Hospital, Montpellier | Asthma | 05/25 | 05/25 | | |
MepoRiNaPAs, NCT06069310: Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma |
|
|
| Recruiting | N/A | 60 | Europe | Mepolizumab 100 MG, nucala | National and Kapodistrian University of Athens | Chronic Rhinosinusitis With Nasal Polyps, Severe Eosinophilic Asthma, Chronic Rhinosinusitis Without Nasal Polyps | 09/25 | 12/25 | | |
| Recruiting | N/A | 100 | Europe | Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval) | University Hospital, Lille | Chronic Rhinosinusitis With Nasal Polyps | 07/27 | 07/27 | | |
ACTRN12621000113853p: Effect of mepolizumab on alternative functions of eosinophils in severe eosinophilic asthma |
|
|
| Not yet recruiting | N/A | 80 | | | University of Newcastle, Glaxo Smith Kline | Severe asthma | | | | |
ACTRN12621001333808: Mepolizumab for treatment of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - A pilot study |
|
|
| Recruiting | N/A | 8 | | | St Vincent's Hospital, Sydney, Glaxo Smith Kline Research & Development Ltd, Balnaves Foundation | DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome | | | | |
NCT05091385: Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma |
|
|
| Not yet recruiting | N/A | 130 | Europe | Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019 | Medical University of Lodz, GlaxoSmithKline | Asthma; Eosinophilic | 12/21 | 12/21 | | |
| Not yet recruiting | N/A | 60 | Europe | Mepolizumab | University Hospital Southampton NHS Foundation Trust, GlaxoSmithKline | Asthma; Eosinophilic | 12/22 | 12/22 | | |
IMPOSE, NCT05147155: Impulse Oscillometry Measurements in Severe Eosinophilic Asthmatics Before and After Anti-IL-5 Factor Initiation |
|
|
| Completed | N/A | 40 | Europe | Mepolizumab, Nucala | University of Thessaly | Severe Asthma | 10/23 | 10/23 | | |
IRIS, NCT05144087: The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma |
|
|
| Not yet recruiting | N/A | 18 | NA | | University Hospital Southampton NHS Foundation Trust, King's College London, University of Southampton | Asthma; Eosinophilic | 04/23 | 10/24 | | |
SASAM, NCT05040997: Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Mepolizumab ( Study) |
|
|
| Recruiting | N/A | 40 | Europe | Small airways assessment | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Small Airway Disease, Asthma | 05/23 | 05/23 | | |
ACTRN12621000113853: Effect of mepolizumab on alternative functions of eosinophils in severe eosinophilic asthma |
|
|
| Completed | N/A | 80 | | | University of Newcastle, Glaxo Smith Kline | Severe asthma | | | | |
CSAREA, NCT05241769: The Influence of Inhaled CorticoSteroids Adherence on Treatment Response to Mepolizumab in Severe Eosinophilic Asthma |
|
|
| Not yet recruiting | N/A | 250 | NA | | University Hospital Birmingham | Asthma; Eosinophilic | 09/23 | 09/23 | | |
NCT05689931: Blood Leukocyte Profiling in Eosinophilic Type 2 Asthma: Influence of Systemic IL-5 Targeting |
|
|
| Recruiting | N/A | 80 | Europe | Mepolizumab, Mepolizumab (brand name: Nucala), Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA), ICS and LABA | Region Skane, Lund University | Asthma | 04/24 | 12/24 | | |
| Recruiting | N/A | 102 | Europe | | University Hospital, Lille, GlaxoSmithKline | Asthma, Asthma; Eosinophilic | 02/25 | 07/25 | | |
NCT05365841: Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). |
|
|
| Recruiting | N/A | 85 | Europe | Mepolizumab 100 MG | University of Crete | Severe Eosinophilic Asthma w/wo CRSwNP | 05/25 | 11/25 | | |
CALIOPI, NCT05708300: Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma |
|
|
| Recruiting | N/A | 57 | Europe | Mepolizumab 100 MG [Nucala], biologicals/vaccine | Aristotle University Of Thessaloniki, 1st ORL Department, AHEPA Hospital, Aristotle University of Thessaloniki, Department of Otorhinolaryngology, Head and Neck Surgery, George Papanikolaou Hospital, Department of Otorhinolaryngology, Democritus University of Thrace, Alexandroupolis, Department of Pulmonology, Democritus University of Thrace, Alexandroupolis, Respiratory Medicine Department, University of Ioannina, Faculty of Medicine, Department of Respiratory Medicine, National and Kapodistrian University of Athens, Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Department of Otolaryngology, Head and Neck Surgery, Sotiria General Hospital, Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens | Chronic Rhinosinusitis With Nasal Polyps, Asthma | 03/26 | 03/27 | | |